登录

雀巢、雷迪博士将成立合资公司,在印度销售营养品品牌

Nestle, Dr Reddy's to form JV to market nutraceutical brands in India

economictimes.indiatimes | 2024-04-25 | 翻译由动脉网AI生成,点击反馈

可切换为仅中文


Nestle India and Dr. Reddy’s on Thursday announced that they have entered into a definitive agreement to form a joint venture (JV) to bring innovative nutraceutical brands to consumers in India and other agreed territories. The partnership will bring together the well-known global range of nutritional health solutions as well as vitamin, minerals, herbals and supplements of Nestle Health Science (NHSc) and also leverage the commercial capabilities of Dr.

雀巢印度公司(Nestle India)和Reddy博士(Dr.Reddy's)周四宣布,他们已达成最终协议,成立一家合资企业(JV),为印度和其他商定地区的消费者带来创新的营养保健品牌。该合作关系将汇集雀巢健康科学(NHSc)全球知名的营养健康解决方案以及维生素、矿物质、草药和补充剂,并利用Dr。

Reddy’s. Select brands will be licensed by the JV partners to the JV company. The Nestle Group will license brands such as Nature's Bounty, Osteo Bi-Flex, Ester-C, Resource High Protein, Optifast, Resource Diabetic, Peptamen, Resource Renal and Resource Dialysis. Dr. Reddy’s will license brands such as Rebalanz, Celevida, Antoxid, Kidrich-D3, Becozinc in the nutrition, and OTC segments.

雷迪的。选定的品牌将由合资伙伴授权给合资公司。雀巢集团将授权Nature's Bounty、Osteo Bi Flex、Ester-C、Resource High Protein、Optifast、Resource Diabetic、Peptamen、Resource Renal和Resource Dialysis等品牌。Reddy博士将授权Rebalanz、Celevida、Antoxid、Kidrich-D3、Becozinc等品牌进入营养和非处方药领域。

The JV company will be headquartered in Hyderabad is expected to become operational in Q2 of FY25.“This joint venture will enable us to build a robust retail and distribution network to take our brands closer to consumers and making a meaningful difference to improve the quality of life,” said Suresh Narayanan, chairman and managing director, Nestlé India.“This novel approach of leveraging mutually complementary strengths of both parent companies will enable better access and affordability for consumers,' said M.V.

该合资公司将总部设在海得拉巴,预计将于25财年第二季度开始运营。“这家合资公司将使我们能够建立一个强大的零售和分销网络,使我们的品牌更接近消费者,并为改善生活质量做出有意义的贡献,”雀巢印度董事长兼董事总经理Suresh Narayanan表示。M.V.说:“这种利用两家母公司互补优势的新方法将使消费者能够更好地获得和负担得起。”。

Ramana, CEO – Branded Markets (India & Emerging Markets), Dr. Reddy’s.(You can now subscribe to our Economic Times WhatsApp channel)(You can now subscribe to our Economic Times WhatsApp channel).

Ramana,品牌市场(印度和新兴市场)首席执行官,Reddy博士。(您现在可以订阅我们的经济时报WhatsApp频道)(您现在可以订阅我们的经济时报WhatsApp频道)。

推荐阅读

KKR正在谈判收购医疗保健BPO公司Infinx

economictimes.indiatimes 2024-05-20 04:10

专注于中枢神经系统的Rapport Therapeutics Preps首次公开募股支持2期癫痫药物

MedCity News 2024-05-20 04:09

年入1222亿,雅培医疗器械

思宇MedTech 2024-05-20 00:15

economictimes.indiatimes

231篇

最近内容 查看更多

KKR正在谈判收购医疗保健BPO公司Infinx

8 小时后

Dr Reddy’s、Sun Pharma和Aurobindo在美国召回产品

6 小时前

Serum Partners美国公司将推进无针注射技术

2 天前

产业链接查看更多

所属赛道

保健品及其它